Sofía España
YOU?
Author Swipe
View article: Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer
Same mutation, different fates: The Yin-Yang of BRAF-driven therapeutic responses in melanoma and colorectal cancer Open
BRAF mutations are key oncogenic drivers across multiple cancers, yet their therapeutic exploitation varies markedly by tumor type. In melanoma, the combination of BRAF and MEK inhibitors has revolutionized treatment, yielding unprecedente…
View article: Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study Open
Pyrexia is the most common adverse event in patients treated with dabrafenib plus trametinib. However, the pathogenesis of pyrexia and factors to identify patients at higher risk of developing pyrexia remain unknown. The ELDERLYMEL study w…
View article: Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience
Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience Open
Background Targeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors…
View article: Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance? Open
Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum p…
View article: Lymphadenopathy after COVID-19 vaccine mimicking lymph-node progression in a patient with metastatic melanoma
Lymphadenopathy after COVID-19 vaccine mimicking lymph-node progression in a patient with metastatic melanoma Open
Citation: Verdaguer Faja J, Manzano JL, España S, Notta PC, Rodriguez Iniesta RV, Boada A. Lymphadenopathy After COVID-19 Vaccine Mimicking Lymph Node Progression in a Patient With Metastatic Melanoma. Dermatol Pract Concept. 2022;12(4):e2…
View article: A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study
A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study Open
The Naloxegol Cancer Study (NACASY) was a multinational European study aimed to evaluate the 4-week safety and efficacy of naloxegol in a real-world setting in patients with cancer pain diagnosed with opioid-induced constipation. The prima…
View article: <p>PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate</p>
PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate Open
Our results indicate an association between PSA kinetics, especially early PSA response, and outcome to AA after progression to docetaxel. Taken together with other factors, lack of an early PSA response could identify patients who are unl…
View article: Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution
Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution Open
The incidence of EIR-AE in our study is similar to other series. Patients who develop EIR-AE might have a better prognosis compared to those who do not experience them.
View article: Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients Open
T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer pat…